Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants.


Journal

Journal of molecular biology
ISSN: 1089-8638
Titre abrégé: J Mol Biol
Pays: Netherlands
ID NLM: 2985088R

Informations de publication

Date de publication:
31 05 2019
Historique:
received: 19 12 2018
revised: 10 04 2019
accepted: 23 04 2019
pubmed: 6 5 2019
medline: 24 3 2020
entrez: 4 5 2019
Statut: ppublish

Résumé

A variety of amino acid substitutions in the NS3-4A protease of the hepatitis C virus lead to protease inhibitor (PI) resistance. Many of these significantly impair the replication fitness of the resistant variants in a genotype- and subtype-dependent manner, a critical factor in determining the probability with which resistant variants will persist. However, the underlying molecular mechanisms are unknown. Here, we present a novel residue-interaction network approach to determine how near-neighbor interactions of PI resistance mutations in NS3-4A can impact protease functional sites dependent on their genomic background. We constructed subtype-specific consensus residue networks for subtypes 1a and 1b from protease structure ensembles combined with biological properties of protein residues and evolutionary amino acid conservation. By applying local and global network topology analysis and visual exploration, we characterize PI resistance-associated sites and outline differences in near-neighbor interactions. We find local residue-interaction patterns and features at protease functional sites that are subtype specific. The noncovalent bonding patterns indicate higher fitness costs conferred by PI resistance mutations in a subtype 1b genomic background and explain the prevalence of Q80K and R155K in subtype 1a. Based on local residue interactions, we predict a subtype-specific role for the protease residue NS3-Q80 in molecular mechanisms related to the assembly of infectious virus particles that is supported by experimental data on the capacity of Q80K variants to replicate and produce infectious virus in subtype 1a and 1b cell culture.

Identifiants

pubmed: 31051172
pii: S0022-2836(19)30242-6
doi: 10.1016/j.jmb.2019.04.034
pmc: PMC6554042
mid: NIHMS1528239
pii:
doi:

Substances chimiques

Antiviral Agents 0
Protease Inhibitors 0
Viral Nonstructural Proteins 0
NS3-4A serine protease, Hepatitis C virus EC 3.4.-
Serine Proteases EC 3.4.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2354-2368

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI115207
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Structure. 1999 Nov 15;7(11):1353-63
pubmed: 10574797
J Biol Chem. 2000 Mar 10;275(10):7152-7
pubmed: 10702283
Proteins. 2002 Aug 1;48(2):227-41
pubmed: 12112692
J Virol. 2002 Dec;76(24):13001-14
pubmed: 12438626
Nat Rev Genet. 2004 Feb;5(2):101-13
pubmed: 14735121
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2992-7
pubmed: 15710891
J Biol Chem. 2005 May 27;280(21):20483-92
pubmed: 15767257
Nature. 2005 Oct 20;437(7062):1167-72
pubmed: 16177806
Nucleic Acids Res. 2007 Jan;35(Database issue):D363-6
pubmed: 17142229
J Med Chem. 2007 May 17;50(10):2310-8
pubmed: 17444623
J Biol Chem. 2007 Aug 3;282(31):22619-28
pubmed: 17556358
Antimicrob Agents Chemother. 2008 Jan;52(1):110-20
pubmed: 17938182
Bioinformatics. 2008 Jan 15;24(2):282-4
pubmed: 18006545
Genome Biol. 2008 Jan 23;9(1):R16
pubmed: 18215275
Curr Protein Pept Sci. 2008 Feb;9(1):28-38
pubmed: 18336321
J Biol Chem. 2008 Oct 31;283(44):29929-37
pubmed: 18723512
Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):67-72
pubmed: 19116270
Cell. 2009 Aug 21;138(4):774-86
pubmed: 19703402
Angew Chem Int Ed Engl. 2010 Feb 22;49(9):1652-5
pubmed: 20166108
Gastroenterology. 2011 Feb;140(2):667-75
pubmed: 21056040
Trends Biochem Sci. 2011 Apr;36(4):179-82
pubmed: 21345680
J Virol. 2011 Jul;85(13):6106-16
pubmed: 21507982
J Virol. 2011 Aug;85(16):7989-8001
pubmed: 21680513
J Clin Virol. 2011 Dec;52(4):321-7
pubmed: 21924672
Nat Protoc. 2012 Mar 15;7(4):670-85
pubmed: 22422314
PLoS Pathog. 2012;8(7):e1002832
pubmed: 22910833
Nat Chem Biol. 2012 Nov;8(11):920-5
pubmed: 23023261
Nucleic Acids Res. 2013 Jan;41(Database issue):D475-82
pubmed: 23193259
Nucleic Acids Res. 2013 Jan;41(Database issue):D36-42
pubmed: 23193287
Clin Infect Dis. 2013 Jul;57(2):221-9
pubmed: 23575197
Nat Rev Microbiol. 2013 Jul;11(7):482-96
pubmed: 23748342
Antimicrob Agents Chemother. 2014;58(2):698-705
pubmed: 24217701
Gastroenterology. 2014 Aug;147(2):366-76.e6
pubmed: 24727022
Gastroenterology. 2014 Aug;147(2):453-62.e7
pubmed: 24768676
Drug Discov Today Technol. 2014 Mar;11:19-25
pubmed: 24847649
J Virol. 2014 Sep;88(18):10970-4
pubmed: 24965468
Nat Med. 2014 Aug;20(8):927-35
pubmed: 25064127
J Virol. 2014 Oct;88(20):12098-111
pubmed: 25122776
BMC Proc. 2014 Aug 28;8(Suppl 2 Proceedings of the 3rd Annual Symposium on Biologica):S2
pubmed: 25237389
J Hepatol. 2015 May;62(5):1008-14
pubmed: 25445400
J Hepatol. 2015 Apr;62(4):779-84
pubmed: 25463536
Antiviral Res. 2015 Apr;116:10-6
pubmed: 25614456
J Virol. 2015 May;89(10):5362-70
pubmed: 25740995
Nucleic Acids Res. 2015 Jul 1;43(W1):W580-4
pubmed: 25845596
Clin Infect Dis. 2016 Jan 1;62(1):32-6
pubmed: 26371152
J Hepatol. 2016 Feb;64(2):292-300
pubmed: 26453968
Antimicrob Agents Chemother. 2015 Dec 07;60(2):1106-13
pubmed: 26643326
J Hepatol. 2017 Jan;66(1):153-194
pubmed: 27667367
Gastroenterology. 2017 Jul;153(1):113-122
pubmed: 28390869
Cell. 1996 Oct 18;87(2):343-55
pubmed: 8861917
Protein Sci. 1998 Apr;7(4):837-47
pubmed: 9568891
J Mol Biol. 1999 Jan 29;285(4):1711-33
pubmed: 9917407
J Mol Biol. 1999 Jan 29;285(4):1735-47
pubmed: 9917408

Auteurs

Nadezhda T Doncheva (NT)

Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarbrücken, Germany; Graduate School of Computer Science, Saarland University, Saarbrücken, Germany.

Francisco S Domingues (FS)

Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy.

David R McGivern (DR)

Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Tetsuro Shimakami (T)

Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.

Stefan Zeuzem (S)

Department of Internal Medicine 1, Goethe University Hospital Frankfurt, Frankfurt a.M., Germany.

Thomas Lengauer (T)

Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarbrücken, Germany.

Christian M Lange (CM)

Department of Internal Medicine 1, Goethe University Hospital Frankfurt, Frankfurt a.M., Germany.

Mario Albrecht (M)

Institute for Knowledge Discovery, Graz University of Technology, Graz, Austria.

Christoph Welsch (C)

Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarbrücken, Germany; Department of Internal Medicine 1, Goethe University Hospital Frankfurt, Frankfurt a.M., Germany. Electronic address: christoph.welsch@kgu.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH